Correspondence 0001213900-26-062830 from Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc.
Date: May 29, 2026 · CIK: 0001506251 · Accession: 0001213900-26-062830
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296195
Letter
CITIUS PHARMACEUTICALS, INC.
11 Commerce Drive, First Floor
Cranford, NJ 07016
May 29, 2026
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
Re:
Acceleration Request Citius Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 22, 2026 File No. 333-296195
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), Citius Pharmaceuticals, Inc. (the "Registrant") hereby requests that the U.S. Securities and Exchange Commission (the "Commission") take appropriate action to accelerate the effective date of the above-referenced registration statement (the "Registration Statement") so as to become effective on Tuesday, June 2, 2026 at 4:15 p.m. Eastern Time, or as soon thereafter as practicable.
The Registrant hereby authorizes Lorna A. Knick or Christopher Agoranos of Wyrick Robbins Yates & Ponton LLP to orally modify or withdraw this request for acceleration.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Christopher Agoranos at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Mr. Agoranos via email at cagoranos@wyrick.com.
Sincerely,
CITIUS PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm CITIUS PHARMACEUTICALS, INC. 11 Commerce Drive, First Floor Cranford, NJ 07016 May 29, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Acceleration Request Citius Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 22, 2026 File No. 333-296195 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), Citius Pharmaceuticals, Inc. (the "Registrant") hereby requests that the U.S. Securities and Exchange Commission (the "Commission") take appropriate action to accelerate the effective date of the above-referenced registration statement (the "Registration Statement") so as to become effective on Tuesday, June 2, 2026 at 4:15 p.m. Eastern Time, or as soon thereafter as practicable. The Registrant hereby authorizes Lorna A. Knick or Christopher Agoranos of Wyrick Robbins Yates & Ponton LLP to orally modify or withdraw this request for acceleration. Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Christopher Agoranos at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Mr. Agoranos via email at cagoranos@wyrick.com. Sincerely, CITIUS PHARMACEUTICALS, INC. By: /s/ Jaime Bartushak Jaime Bartushak Chief Financial Officer cc: Christopher Agoranos, Wyrick Robbins Yates & Ponton LLP